TY - JOUR
T1 - Inhibitors of mTOR
AU - Klümpen, Heinz-Josef
AU - Beijnen, Jos H.
AU - Gurney, Howard
AU - Schellens, Jan H. M.
PY - 2010
Y1 - 2010
N2 - Inhibitors of mammalian target of rapamycin (mTOR) have been approved for the treatment of renal cell carcinoma and appear to have a role in the treatment of other malignancies. The primary objective of this drug review is to provide pharmacokinetic and dynamic properties of the commonly used drugs everolimus and temsirolimus. Additionally, information on clinical use, mechanism of action, bioanalysis, drug-drug interactions, alterations with disease or age, pharmacogenetics, and drug resistance is given. This overview should assist the treating medical oncologist in adjusting treatment with mTOR inhibitors to individual patient circumstances. The Oncologist 2010;15:1262-1269
AB - Inhibitors of mammalian target of rapamycin (mTOR) have been approved for the treatment of renal cell carcinoma and appear to have a role in the treatment of other malignancies. The primary objective of this drug review is to provide pharmacokinetic and dynamic properties of the commonly used drugs everolimus and temsirolimus. Additionally, information on clinical use, mechanism of action, bioanalysis, drug-drug interactions, alterations with disease or age, pharmacogenetics, and drug resistance is given. This overview should assist the treating medical oncologist in adjusting treatment with mTOR inhibitors to individual patient circumstances. The Oncologist 2010;15:1262-1269
U2 - https://doi.org/10.1634/theoncologist.2010-0196
DO - https://doi.org/10.1634/theoncologist.2010-0196
M3 - Review article
C2 - 21147869
SN - 1083-7159
VL - 15
SP - 1262
EP - 1269
JO - oncologist
JF - oncologist
IS - 12
ER -